Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOTABLE-308: nimotuzumab plus trifluridine/tipiracil for third-line or later metastatic colorectal cancer
CTR20241261Phase 3Suspended
- Sponsor
- Biotech Pharmaceutical
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nimotuzumab in colorectal cancer (CRC), metastatic colorectal adenocarcinoma (mCRC), sponsored by Biotech Pharmaceutical. Started Apr 2024; status: suspended.
02
Drugs
nimotuzumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on CTR20241261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241261.